Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
A Phase I study to assess the safety and tolerability of AZD2281 in combination with
Cisplatin in patients with advanced Solid Tumours. This is an open label-dose finding; to
establish the maximum tolerated dose of AZD2281 combined with Cisplatin in patients with
advanced solid tumours. Approximately 50 (max 60) patients from 2 countries will be enrolled